IX
IXHL.US Incannex Healthcare Inc.
- Market cap
- USD 24.7M
- P/E
- -
- P/B
- 0.37x
- ROE
- -11.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is IXHL.US undervalued?
Graham numberThe Graham number of Incannex Healthcare Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Incannex Healthcare Inc. fundamental analysis
No fundamental analysis for Incannex Healthcare Inc. yet.
Incannex Healthcare Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Incannex Healthcare Inc.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with gen…
Full company profileIncannex Healthcare Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Incannex Healthcare Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 283K | 1.01M | 1.18M | 600K | 1.90M | 785K | 1.01M | 12.0K | 86.0K | 0.00 | - |
| Gross Profit | -235K | 487K | 597K | 153K | 986K | 779K | -88.1K | 12.0K | -160K | -240K | - |
| Operating Income | -21.0M | -3.21M | -2.79M | -4.11M | -8.24M | -11.4M | -20.5M | -30.0M | -23.8M | -23.0M | -13.7M |
| EBITDA | -21.0M | -3.14M | -2.75M | -4.08M | -8.16M | -5.19M | -20.4M | -27.8M | -23.5M | -22.8M | -13.7M |
| Net Income | -20.8M | -2.94M | -2.72M | -4.66M | -8.16M | -14.9M | -73.5M | -18.5M | -46.9M | -19.3M | -7.75M |
| EPS | -20 | -1.55 | -0.73 | -0.27 | -0.33 | -1.50 | -14 | -3.43 | -41 | -1.66 | -0.62 |
| Balance Sheet | |||||||||||
| Total Assets | 1.00M | 712K | 520K | 2.91M | 7.01M | 38.0M | 35.8M | 17.0M | 20.4M | 73.0M | 70.4M |
| Total Liabilities | 1.17M | 1.10M | 939K | 736K | 567K | 2.02M | 4.45M | 5.83M | 7.06M | 5.61M | 4.26M |
| Shareholders' Equity | -169K | -385K | -419K | 2.17M | 6.44M | 36.0M | 31.3M | 11.2M | 13.4M | 67.4M | 66.1M |
| Cash & Short-term Investments | 509K | 230K | 93.7K | 2.48M | 6.85M | 37.5M | 33.3M | 5.86M | 15.0M | 67.7M | 68.3M |
| Total Debt | 399K | 201K | 65.3K | - | - | - | 784K | 373K | 258K | 96.0K | 83.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.70M | -3.00M | -2.21M | -3.89M | -6.87M | -12.9M | -16.2M | -15.8M | -12.5M | -12.9M | 2.08M |
| Capital Expenditure | 50.3K | 50.1K | 24.5K | 477K | 4.15 | 5.23 | 476K | 277K | 8.00K | 10.0K | 0.00 |
| Free Cash Flow | -2.75M | -3.05M | -2.19M | -3.89M | -6.91M | -12.9M | -16.7M | -16.1M | -12.5M | -12.9M | 2.08M |
| Ratios | |||||||||||
| ROE | - | - | - | -214.2% | -126.7% | -41.4% | -234.4% | -164.6% | -350.2% | -28.6% | -11.7% |
| ROA | -2,068.4% | -413.3% | -523.6% | -160.0% | -116.4% | -39.2% | -205.2% | -108.3% | -229.3% | -26.4% | -11.0% |
| Net Profit Margin | -7,336.2% | -291.2% | -230.7% | -776.6% | -430.1% | -1,898.0% | -7,246.0% | -153,825.0% | -54,517.4% | - | - |
| Debt to Equity | - | - | - | - | - | - | 0.03x | 0.03x | 0.02x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Incannex Healthcare Inc. dividends
Incannex Healthcare Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Feb 27, 2026.
Who owns Incannex Healthcare Inc.
- Insiders 9.12%
- Institutions 4.00%
- Public & others 86.88%
- Shares outstanding 12.5M
- Free float 10.5M
Top funds holding IXHL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 156K | 1.25% | 0.00% | Oct 2026 |
| Abante Quant Value FI | 43.3K | 0.35% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 8.64K | 0.07% | 0.00% | Aug 2026 |
Top institutions holding IXHL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| LPL Financial Corp | 148K | 1.18% | +108.18% | Jun 2026 |
| Millennium Management LLC | 95.3K | 0.76% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 78.2K | 0.62% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 60.9K | 0.49% | +148.41% | Jun 2026 |
| Susquehanna International Group, LLP | 28.8K | 0.23% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 14.0K | 0.11% | +15.83% | Jun 2026 |
| Citadel Advisors Llc | 10.3K | 0.08% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 6.38K | 0.05% | 0.00% | Jun 2026 |
| UBS Group AG | 3.61K | 0.03% | -91.06% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.56K | 0.03% | +72.30% | Jun 2026 |
| Citigroup Inc | 2.81K | 0.02% | 0.00% | Jun 2026 |
| Quent Capital, LLC | 1.93K | 0.02% | 0.00% | Jun 2026 |
| Barclays PLC | 750.00 | 0.01% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Larson Financial Group, LLC | 1.00 | 0.00% | -98.31% | Jun 2026 |
| Murchinson Ltd. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Scarborough Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Ghisallo Capital Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Danske Bank A/S. | 0.00 | 0.00% | -100.00% | Jun 2026 |
Incannex Healthcare Inc. company profile
- Company name
- Incannex Healthcare Inc.
- Ticker
- IXHL.US
- Exchange
- USA Stocks
- Listed since
- Mar 2, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- June
- Address
- Rialto South Tower Level 23, Melbourne, VIC, Australia, 2153
- Phone
- 61 4 0984 0786
- Website
- incannex.com
About Incannex Healthcare Inc.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.
Incannex Healthcare Inc. management
7- Mr. Joel Bradley LathamPresident, CEO & Executive Director · born 1989
- Mr. Joseph SwanCFO, Treasurer & Secretary · born 1991
- Dr. Luigi M. Barbato M.D.Chief Medical Officer · born 1963
- Mr. Lekhram Changoer M.Sc.Chief Technology Officer · born 1967
- Dr. Mark Bleackley Ph.D.Chief Scientific Officer, Head of Programs & Member of the Advisory Board
- Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D.Chief Executive Officer of IncannexTM
- Natalie MayHead of Clinical Operations